858 Therapeutics
PrivateLast Round
Series B
Sep 26, 2024
Total Funding Raised
$110M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
858 Therapeutics is a biotechnology company that develops small molecule therapeutics targeting novel oncology and immunology areas, including DNA damage response, innate immunity, and RNA modulation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
858 Therapeutics Comparables
Compare 858 Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| FoRx Therapeutics | 88% | |
| KSQ Therapeutics | 87% | |
| IDEAYA Biosciences, Inc. | 81% |
858 Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 26, 2024 | ||||
| Series A | Sep 21, 2021 |
858 Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| New Enterprise Associates | Series B, Series A |
| Cormorant Asset Management | Series A |
| Avidity Partners | Series B |
| Logos Capital | Series B, Series A |
| Versant Ventures | Series B, Series A |
| Alexandria Venture Investments | Series B |
| Mirae Asset Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 84% MoM, from 1.9K to 3.5K.
- Jun 21, 2026
Monthly visitors increased 35% MoM.
858 Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about 858 Therapeutics's valuation, stock price, and market status.
Is 858 Therapeutics a public or private company?
858 Therapeutics is a private company.
What is the current stock price of 858 Therapeutics?
858 Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is 858 Therapeutics worth (valuation)?
Valuation information for 858 Therapeutics is not publicly available.
Can I buy 858 Therapeutics stock?
858 Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was 858 Therapeutics's last funding round?
858 Therapeutics's most recent funding round was Series B on September 26, 2024.
Who are the main investors in 858 Therapeutics?
Key investors in 858 Therapeutics include Avidity Partners, Versant Ventures.
Will 858 Therapeutics IPO soon?
No public IPO plans have been announced for 858 Therapeutics.
How can I track 858 Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor 858 Therapeutics's secondary market activity and sign up for updates.